...Hi, I'm Louise Chen, the large-cap biopharma analyst here at Cantor. Thank you for joining us today for a virtual fireside chat with Eli Lilly. Lilly is one of the top-performing pharma companies in the sector with a robust portfolio of fast-growing products and a pipeline of first-in-class and/or best-in-class drugs. We think the company's earnings profile continues to look favorable when compared to those of its peers. Its margin expansion profile represents one of the strongest in the pharma industry, with a potential for mid-teens EPS growth. Lilly is entering a period of earnings growth, unencumbered by large loss of exclusivities and bolstered by multiple pipeline readouts of its first-in-class and/or best-in-class compounds. Therefore, we are thrilled to have with us today, CFO, Josh Smiley, to talk about the business....